• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Can­cer vac­cine de­vel­op­er jumps to Nas­daq via re­verse merg­er

3 years ago
Deals

Lat­est news on Covid boost­ers safe­ty sig­nal; As­traZeneca leads trio of M&A; The biggest news out of #JPM23; and more

3 years ago
Weekly

US in­ves­ti­gates po­ten­tial safe­ty sig­nal with Pfiz­er Covid boost­ers

3 years ago
Pharma
FDA+

Cal­i­for­nia sues in­sulin heavy­weights, PBMs over 'ex­ces­sive' prices

3 years ago
Pharma
Law

Ex-Take­da staffer­'s 's­mall hus­tle' ends with ar­rest and $2.3M fraud scheme charge

3 years ago
Pharma
Law

EMA de­vel­op­ing physi­cian guid­ance for po­ten­tial liv­er dam­age af­ter tak­ing Zol­gens­ma

3 years ago
Pharma
Cell/Gene Tx

My­ovant, Pfiz­er de­but first brand­ed cam­paign for prostate can­cer med Or­govyx

3 years ago
Pharma
Marketing

Most trust­ed: Phar­ma over­takes tech in­dus­try for top spot in Ip­sos’ an­nu­al trust­wor­thi­ness sur­vey

3 years ago
Pharma
Marketing

Scoop: Roche-backed start­up gives up on CD47, lays off all em­ploy­ees

3 years ago
People
Startups

In ‘clever’ ex­per­i­ment, sci­en­tists use gene edit­ing to treat heart dis­ease in mice

3 years ago
R&D
Discovery

No­vo Nordisk's GLP-1 for Type II di­a­betes ap­proved for first-line treat­ment

3 years ago
FDA+

No­vavax and Cure­Vac among sev­er­al biotechs with new CEOs; Michel Vounatsos, John Tsai land board ap­point­ments

3 years ago
Peer Review

Dig­i­tal ther­a­peu­tics 2023: Swing and tri­al part­ner Cu­rav­it kick off fi­bromyal­gia study

3 years ago
Pharma
Marketing

Three Ohio-based con­tract or­ga­ni­za­tions win $149M deal for neu­ro­log­i­cal can­di­dates

3 years ago
Deals
Outsourcing

As­traZeneca to dis­con­tin­ue rare blood can­cer drug in the US

3 years ago
Pharma
FDA+

Gal­der­ma dri­ves di­ver­si­ty in der­ma­tol­ogy with on­line pho­to gallery spon­sor­ship

3 years ago
Pharma
Marketing

Alex Den­ner tar­gets Amarin, de­mand­ing board chair re­sign in call for share­hold­er meet­ing

3 years ago
People

Pfiz­er, BioN­Tech team up with Martha Stew­art for Covid boost­er cam­paign

3 years ago
Pharma
Marketing

Li­nus­Bio se­cures Se­ries A for di­ag­nos­tic plat­form that us­es a sin­gle strand of hair

3 years ago
Financing

A Take­da-backed GI and pain biotech qui­et­ly shut­ters

3 years ago
People
Startups

Man­u­fac­tur­ing roundup: Cy­ti­va part­ners with Au­risco to build site for oligonu­cleotides; Eu­roAPI in­vest­ing €40M to ...

3 years ago
Manufacturing

Q&A: Can in­haled vac­cines mount come­back for one-time leader in Chi­na's Covid race?

3 years ago
People
China

WHO is­sues alert over con­t­a­m­i­nat­ed cough syrups

3 years ago
Pharma
Manufacturing

Oramed’s in­sulin pill fails PhI­II tri­al in di­a­betes, stock craters

3 years ago
R&D
First page Previous page 402403404405406407408 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times